XN

Xencor

- NASDAQ:XNCR
Last Updated 2024-04-16

LinkedIn Profile

Access Xencor historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:xncr 38336 Apr 14th, 2024 12:00AM Xencor 8.2K 284.00 Open Apr 13th, 2024 11:55PM Apr 14th, 2024 11:53AM Proteins by Design Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. The XmAb® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by Xencor and by pharmaceutical partners. Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs. Open Protein engineering, Drug development, Antibody drugs, Biotechnology, Oncology, Autoimmune disease, Bispecific antibodies, and Cytokines Open 465 N Halstead St Pasadena California US 91107 Xencor Health Care Pharmaceuticals & Biotechnology
nasdaq:xncr 38336 Apr 13th, 2024 12:00AM Xencor 8.2K 284.00 Open Apr 12th, 2024 11:47PM Apr 13th, 2024 12:20PM Proteins by Design Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. The XmAb® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by Xencor and by pharmaceutical partners. Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs. Open Protein engineering, Drug development, Antibody drugs, Biotechnology, Oncology, Autoimmune disease, Bispecific antibodies, and Cytokines Open 465 N Halstead St Pasadena California US 91107 Xencor Health Care Pharmaceuticals & Biotechnology
nasdaq:xncr 38336 Apr 12th, 2024 12:00AM Xencor 8.2K 282.00 Open Apr 11th, 2024 11:54PM Apr 12th, 2024 09:16AM Proteins by Design Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. The XmAb® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by Xencor and by pharmaceutical partners. Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs. Open Protein engineering, Drug development, Antibody drugs, Biotechnology, Oncology, Autoimmune disease, Bispecific antibodies, and Cytokines Open 465 N Halstead St Pasadena California US 91107 Xencor Health Care Pharmaceuticals & Biotechnology
nasdaq:xncr 38336 Apr 11th, 2024 12:00AM Xencor 8.2K 282.00 Open Apr 11th, 2024 12:50AM Apr 11th, 2024 12:01PM Proteins by Design Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. The XmAb® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by Xencor and by pharmaceutical partners. Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs. Open Protein engineering, Drug development, Antibody drugs, Biotechnology, Oncology, Autoimmune disease, Bispecific antibodies, and Cytokines Open 465 N Halstead St Pasadena California US 91107 Xencor Health Care Pharmaceuticals & Biotechnology
nasdaq:xncr 38336 Apr 10th, 2024 12:00AM Xencor 8.1K 282.00 Open Apr 9th, 2024 11:55PM Apr 10th, 2024 06:08PM Proteins by Design Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. The XmAb® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by Xencor and by pharmaceutical partners. Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs. Open Protein engineering, Drug development, Antibody drugs, Biotechnology, Oncology, Autoimmune disease, Bispecific antibodies, and Cytokines Open 465 N Halstead St Pasadena California US 91107 Xencor Health Care Pharmaceuticals & Biotechnology
nasdaq:xncr 38336 Apr 9th, 2024 12:00AM Xencor 8.1K 282.00 Open Apr 9th, 2024 12:06AM Apr 9th, 2024 10:50AM Proteins by Design Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. The XmAb® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by Xencor and by pharmaceutical partners. Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs. Open Protein engineering, Drug development, Antibody drugs, Biotechnology, Oncology, Autoimmune disease, Bispecific antibodies, and Cytokines Open 465 N Halstead St Pasadena California US 91107 Xencor Health Care Pharmaceuticals & Biotechnology
nasdaq:xncr 38336 Apr 8th, 2024 12:00AM Xencor 8.1K 282.00 Open Apr 8th, 2024 12:58AM Apr 8th, 2024 07:47PM Proteins by Design Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. The XmAb® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by Xencor and by pharmaceutical partners. Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs. Open Protein engineering, Drug development, Antibody drugs, Biotechnology, Oncology, Autoimmune disease, Bispecific antibodies, and Cytokines Open 465 N Halstead St Pasadena California US 91107 Xencor Health Care Pharmaceuticals & Biotechnology
nasdaq:xncr 38336 Apr 7th, 2024 12:00AM Xencor 8.1K 281.00 Open Apr 7th, 2024 12:00AM Apr 7th, 2024 12:00AM Proteins by Design Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. The XmAb® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by Xencor and by pharmaceutical partners. Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs. Open Protein engineering, Drug development, Antibody drugs, Biotechnology, Oncology, Autoimmune disease, Bispecific antibodies, and Cytokines Open 465 N Halstead St Pasadena California US 91107 Xencor Health Care Pharmaceuticals & Biotechnology
nasdaq:xncr 38336 Apr 6th, 2024 12:00AM Xencor 8.1K 281.00 Open Apr 6th, 2024 12:00AM Apr 6th, 2024 12:00AM Proteins by Design Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. The XmAb® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by Xencor and by pharmaceutical partners. Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs. Open Protein engineering, Drug development, Antibody drugs, Biotechnology, Oncology, Autoimmune disease, Bispecific antibodies, and Cytokines Open 465 N Halstead St Pasadena California US 91107 Xencor Health Care Pharmaceuticals & Biotechnology
nasdaq:xncr 38336 Apr 5th, 2024 12:00AM Xencor 8.1K 281.00 Open Apr 5th, 2024 01:09AM Apr 5th, 2024 01:09AM Proteins by Design Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. The XmAb® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by Xencor and by pharmaceutical partners. Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs. Open Protein engineering, Drug development, Antibody drugs, Biotechnology, Oncology, Autoimmune disease, Bispecific antibodies, and Cytokines Open 465 N Halstead St Pasadena California US 91107 Xencor Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.